NTRK-inhibitor
Since April 1 and October 1, 2021 there is a reimbursement of respectively Larotrectinib (Vitrakvi ®) and Entrectinib (Rozlytrek) by the RIZIV/INAMI. Larotrectinib and Entrectinib are used to treat adult and/or pediatric patients with locally advanced or metastatic solid tumors with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion which cannot be treated satisfactorily with the available treatment options.
The target group is defined as follows:
patients with Belgian health Insurance
with a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation
of which the tumor is locally advanced or metastatic, or the surgical resection is likely to result in severe morbidity
that do not have satisfactory alternative treatments
after approval by a multidisciplinary oncology consultation (MOC)
The reimbursement can be granted based on an electronic application via the eHealth platform.
This reimbursement is linked to a mandatory registration of tumor and outcome-specific variables via the Belgian Cancer Registry. There are 3 registration time points:
At the latest 1 month after the eHealth application for the NTRK-inhibitor treatment:
registration form At the latest 6 months after the end of the NTRK-inhibitor treatment:
registration form If the patient is still being treated with
Larotrectinib on September 15, 2023:
registration form If the patient is still being treated with
Entrectinib on March 15, 2024:
registration form
Detailed information about these specific requested variables and some 'Frequently Asked Questions' are available in the project manual.
Registrations can be submitted from 01/04/2021 via the Web Based Cancer Registration (WBCR) application of the Belgian Cancer Registry (project module "NTRK-inhibitor"). More information about the usage of this application is available in the WBCR manual.
If you would like more information about the NTRK-inhibitor registration project, please contact us via NTRKinhibitor@kankerregister.org or via 02/212 08 55.